Samarium is a type of metal, like a rare earth metal. It's used in some nuclear power plants as a material in the control rods to help manage the reaction. It's not something people typically encounter in everyday life.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Samarium is a rare-earth metal. The element itself is not a medicine, but a radioactive form of it, samarium-153, is the active part of samarium-153 lexidronam, sold in the US under the brand name Quadramet. It is approved to relieve pain from cancer that has spread to the bones (bone metastases), specifically the bone-building (osteoblastic) kind of metastases that show up on a bone scan. In the trials behind its approval, most people had prostate cancer, and all had bone pain that other treatments had not controlled well. Samarium-153 treats pain, not the cancer itself. The US Food and Drug Administration (FDA) now lists Quadramet as discontinued, so it is rarely offered in the US today. Other ways to manage bone metastasis pain include pain medicines and external beam radiation aimed at a painful area. For prostate cancer that no longer responds to hormone-lowering treatment, has spread to bone and causes symptoms, but has not spread to organs such as the liver or lungs, radium-223 (Xofigo) is a related radioactive medicine.
Cancer in bone often makes the surrounding bone break down and rebuild faster than normal. Samarium-153 is attached to a carrier called EDTMP, a phosphonate compound that clings to bone in these areas of active turnover. After an injection into a vein, about two-thirds of the dose settles in the skeleton, and osteoblastic metastases take up roughly five times as much as normal bone. Whatever does not reach bone leaves the body in the urine, mostly within the first several hours. Samarium-153 gives off beta radiation that travels only a few millimeters, so most of its dose lands on bone close to where it has collected. It loses half of its radioactivity about every two days. Exactly why this relieves pain is not known. The same short-range radiation also reaches the bone marrow, where blood cells are made, which explains its main side effect.
Samarium-153 is given once, as an injection into a vein over about a minute, by a nuclear medicine team licensed to handle radioactive drugs. The dose is calculated from body weight. Beforehand, you drink (or receive through an IV) at least two cups of fluid, and afterward you are encouraged to urinate often. This helps clear the radioactivity that does not settle in bone and limits radiation to the bladder. For about 12 hours after the injection, urine carries radioactivity. During that time, use a toilet rather than a urinal, flush it several times after each use, clean up any spilled urine completely and wash your hands well. Clothing with urine or blood on it should be washed separately or stored for one to two weeks to let the radioactivity fade. People who have trouble controlling their bladder may need a urinary catheter during this period.
The most important effect is on the bone marrow. Within 3 to 5 weeks, white blood cell and platelet counts typically fall to around half of their starting levels, then usually recover by about 8 weeks. White blood cells fight infection and platelets help blood clot, so while counts are low, infections and bleeding are more likely. The care team checks blood counts weekly, starting about two weeks after the injection, for at least 8 weeks or until they recover. Contact the care team promptly about fever or chills, unusual bruising, nosebleeds or other bleeding during this period. Some people (about 7 in 100 in trials) have a temporary flare of bone pain within three days of the injection. It is usually mild and eases with pain medicine. Diarrhea and nausea were also reported, although nausea was no more common than with a placebo. Samarium-153 does not prevent spinal cord compression, a complication in which cancer in the spine presses on the spinal cord. New weakness or numbness in the legs, difficulty walking, or loss of bladder or bowel control in someone with cancer in the spine needs emergency care right away, because prompt treatment can prevent permanent disability.
Chemotherapy and external beam radiation also suppress the bone marrow, so samarium-153 is generally not given at the same time as either one, or after them before blood counts have recovered, unless the expected benefit outweighs the risk. People whose marrow is already weakened by earlier treatment or by cancer in the marrow face a higher risk, and the team reviews recent blood counts before deciding. It is not used in people who are allergic to EDTMP or similar phosphonate compounds. EDTMP can bind calcium, and in trials about a third of people whose calcium was measured had at least one low reading soon after the injection, so extra caution is needed for anyone already prone to low calcium. The extra fluids given with treatment need care in people with heart failure, and kidney problems may slow how quickly the radioactivity is cleared. Like other radioactive medicines, samarium-153 can harm a developing baby. People who could become pregnant need a negative pregnancy test beforehand, and both men and women are advised to use effective contraception afterward. Breastfeeding should be replaced with formula feeding if the treatment is given.
Pain relief, when it comes, usually starts about a week after the injection and is greatest at 3 to 4 weeks. Not everyone responds. In the main trials, about half of treated people had less pain without needing more pain medicine at weeks 3 and 4, compared with about a quarter of those given a placebo. People whose pain improves may be able to cut back on opioid pain medicine, a change best made with the care team. The weeks after treatment center on blood tests while counts dip and recover. Because samarium-153 is a pain treatment rather than a cancer treatment, it works alongside the rest of cancer care, not in place of it. The evidence for this group of bone-seeking radioactive treatments is modest and mostly older, and with Quadramet discontinued in the US, a care team is more likely to suggest radiation to specific painful sites, other medicines or, for some prostate cancers, radium-223.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Samarium, what you've noticed, or ask the community a question.